Apical control of transvascular delivery of prosthetic mitral valve

Abstract

Apparatus and methods are described herein for use in the delivery and deployment of a prosthetic mitral valve. In some embodiments, after a prosthetic valve (1500) has been at least partially delivered from a delivery sheath into the left atrium of a heart, a valve positioning device can be used to engage with and position the prosthetic valve within the mitral annulus. The valve positioning device can include a alignment member (1576) configured to engage with a prosthetic valve such that the alignment member can control the distal, proximal, lateral and / or rotational movement of the prosthetic valve. The prosthetic valve can include a tether (1536) that can be inserted or threaded through the alignment member such that the alignment member can be moved along the tether into engagement with the prosthetic valve.

Description

[0001] Cross References to Related Applications [0002] This application claims U.S. Provisional Application No. 62 / 264562, filed December 8, 2015, entitled "Apical Control of Transvascular Delivery of Prosthetic Mitral Valve," and filed June 5, 2015, entitled "Stopper Tube Apparatus and Methods for Delivery of Prosthetic Mitral Valve", the disclosure of which is incorporated by reference in its entirety into this application. [0003] This application is also related to U.S. Provisional Patent Application No. 61 / 935,899, filed February 5, 2014, entitled "Transfemoral Delivery of Prosthetic Mitral Valve," and filed January 7, 2015, entitled "Apparatus and Methods for Transfemoral Delivery of Prosthetic Mitral Valve", U.S. Provisional Patent Application No. 62 / 100548 and International Patent Application No. PCT / US2015 / 014572, filed February 5, 2015, entitled "Apparatus and Methods for Transfemoral Delivery of Prosthetic Mitral Valve" and filed at International Patent Applicatio...

AI Technical Summary

Problems solved by technology

Although valve replacement surgery generally carries a mortality risk of 1-4% in an otherwise healthy population, the procedure is associated with significantly higher morbidity mainly due to the necessity of cardiopulmonary bypass

Also, older patients are often less able to tolerate open-heart surgery

Therefore, elimination of extracorporeal components of the procedure may lead to a reduction in the morbidity of valve replacement therapy and may significantly reduce the cost of valve replacement therapy

[0006] While transcatheter aortic valve replacement is a topic worthy of further investigation, less attention has been given to the mitral valve

Images